ProQR Therapeutics N.V.
Organization details
- Legal name
- ProQR Therapeutics N.V.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Netherlands
- Headquarters city
- Leiden
- Headquarters country
- Netherlands
- Fiscal year end
- December
- Ticker symbol
- PRQR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001612940
Board of directors
-
Alison Frances Lawton · DirectorSince 2026
-
Bart Filius · DirectorSince 2026
-
Begona Carreno-Gomez · DirectorSince 2026
-
Boer Daniel Anton De · Director · Chief Executive OfficerSince 2026
-
Domenico Valerio · DirectorSince 2026
-
Gerardus Johannes Platenburg · Director · Chief Scientific OfficerSince 2026
-
Gylvin Lykke Hinsch · DirectorSince 2026
-
James Samuel Shannon · DirectorSince 2026
-
Martin Alexander Maier · DirectorSince 2026
-
Theresa Heggie · DirectorSince 2026
Chief executives
Board connections
3 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
BioCryst Pharmaceuticals Inc. Same sectorvia Theresa Heggie
-
Dianthus Therapeutics Inc. Same sectorvia Alison Frances Lawton
-
MannKind Corporation Same sectorvia James Samuel Shannon
-
Spyre Therapeutics Inc. Same sectorvia Alison Frances Lawton
-
X4 Pharmaceuticals Inc. Same sectorvia Alison Frances Lawton
-
Xilio Therapeutics Inc. Same sectorvia James Samuel Shannon
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,342,500
- 5 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | Boer Daniel Anton De Director, Officer (Chief Executive Officer) | Open-market purchase | +200,000 | $1.77 | $354,000 |
| Jul 17, 2026 | Bart Filius Director | Open-market purchase | +150,000 | $1.72 | $258,000 |
| Jul 9, 2026 | Boer Daniel Anton De Director, Officer (Chief Executive Officer) | Open-market purchase | +150,000 | $1.74 | $261,000 |
| Jul 7, 2026 | Boer Daniel Anton De Director, Officer (Chief Executive Officer) | Open-market purchase | +150,000 | $1.59 | $238,500 |
| Jun 26, 2026 | Bart Filius Director | Open-market purchase | +150,000 | $1.54 | $231,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about ProQR Therapeutics N.V.
Who is the CEO of ProQR Therapeutics N.V.?
Boer Daniel Anton De has been ProQR Therapeutics N.V.'s Chief Executive Officer since March 2026.
How many directors are on ProQR Therapeutics N.V.'s board?
ProQR Therapeutics N.V.'s board has 10 directors: Alison Frances Lawton, Bart Filius, Begona Carreno-Gomez, Boer Daniel Anton De, Domenico Valerio, Gerardus Johannes Platenburg, Gylvin Lykke Hinsch, James Samuel Shannon, Martin Alexander Maier and Theresa Heggie.
Are ProQR Therapeutics N.V. insiders buying or selling shares?
Over the last 12 months, ProQR Therapeutics N.V. insiders bought $1.3 million of shares in 5 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="proqr-therapeutics-nv"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.